[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"psoriasis-vulgaris\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:psoriasis-vulgaris":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,40,57,80,102,128,161,187,208,257,281,304],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100505230","phase-4-correction-of-psoriatic-t-cell-signatures-by-deucravacitinib-100505230",false,"NCT05858645","Correction of Psoriatic T Cell Signatures by Deucravacitinib","Inclusion Criteria:\n\n1. 18 years of age or older\n2. Patients with moderate-severe psoriasis (BSA \\>= 10%, PASI \\>=12, static Physician's Global Assessment (sPGA) 3 and above)\n\nExclusion Criteria:\n\n1. taking systemic immunosuppressives in the last 12 weeks\n2. pregnancy\n3. severe immunodeficiency (either from genetic or infectious causes).\n4. tuberculosis or other active serious infection\n5. active systemic malignancy.\n6. breast-feeding\n7. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.","ALL","18 Years","75 Years",{"count":19,"type":20},25,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.",[26],"Psoriasis Vulgaris","RECRUITING","2026-06-01",{"date":30,"type":31},"2026-06-04","ACTUAL",{"date":33,"type":31},"2023-10-01",{"date":35,"type":20},"2028-06",{"name":37,"class":38},"University of California, San Francisco","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":51,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":39},"100469262","phase-4-psoriatic-immune-response-to-tildrakizumab-100469262","NCT05390515","Psoriatic Immune Response to Tildrakizumab","Inclusion Criteria:\n\n* 18 years of age or older\n* Patients with moderate-severe psoriasis or \\> 5% body surface area affected.\n\nExclusion Criteria:\n\n* taking systemic immunosuppressives in the last 4 weeks\n* pregnancy\n* severe immunodeficiency (either from genetic or infectious causes).\n* tuberculosis or other active serious infection\n* active systemic malignancy.\n* breast-feeding\n* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.",{"count":47,"type":20},10,[23],"This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.",[26],{"date":30,"type":31},{"date":53,"type":31},"2022-09-01",{"date":55,"type":20},"2028-09-01",{"name":37,"class":38},{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":68,"conditions":69,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":39},"100632679","efficacy-of-topical-metformin-in-psoriasis-vulgaris-100632679","NCT07516821","Efficacy of Topical Metformin in Psoriasis Vulgaris","Efficacy and Safety of Topical Metformin in Psoriasis Vulgaris: A Randomized, Double Blinded, Placebo-controlled Study.","Inclusion criteria:\n\n* Patients ≥ 18 years old\n* Patients of both genders\n* Patients with mild chronic plaque psoriasis ((PASI) \\\u003C 10, and body surface area (BSA) \\\u003C 10% and\u002For Dermatology Life Quality Index (DLQI) \\\u003C10).\n\nExclusion Criteria:\n\n* Intake of anti-psoriatic systemic therapy within the last 3 months apart from retinoids, or topical treatments within the last 2 weeks.\n* Intake of systemic metformin.\n* Intake of other systemic drugs that exacerbate psoriasis as anti-malarial drugs, Angiotensin- converting-enzyme inhibitors (ACEI), Ca channel blockers (CCBs) and beta blockers or intake of non-steroidal anti- inflammatory drugs (NSAID) within the last 2 weeks.\n* Patients with psoriatic arthritis.\n* Patients with pustular psoriasis.\n* Pregnant and Lactating females.",{"count":65,"type":20},55,[67],"NA","The goal of this clinical trial is to learn if topical metformin works to treat mild psoriasis vulgaris. It will also learn about the safety of topical metformin. The main questions it aims to answer are:\n\nDoes topical metformin improve psoriatic plaques in early psoriasis? What medical problems do participants have when use topical metformin? Researchers will compare topical metformin to a placebo (a look-alike substance that contains no drug) to see if topical metformin works to treat psoriasis vulgaris.\n\nParticipants will:\n\nput topical metformin or placebo twice daily for 2 months. Visit the clinic once every months for follow up. Keep a diary of their symptoms and any side effects.\n\nSkin biopsy will be taken from psoriatic plaque before starting treatment and another one will be taken after 2 months of starting treatment to assess the level of IL-17.",[26],"NOT_YET_RECRUITING","2026-04-07",{"date":73,"type":31},"2026-04-13",{"date":75,"type":20},"2026-04-01",{"date":77,"type":20},"2026-09-01",{"name":79,"class":38},"Cairo University",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":15,"minAge":87,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":4},"100631052","pre-post-multimodal-assessment-of-severe-psoriasis-vulgaris-using-clinical-dermoscopic-and-qol-measures-100631052","NCT07495657","Pre-Post Multimodal Assessment Of Severe Psoriasis Vulgaris Using Clinical, Dermoscopic And QoL Measures","Multimodal Evaluation of Severe Psoriasis Vulgaris Before and After Treatment Using Clinical, Dermoscopic, Psoriasis Disability Index, and Quality of Life Parameters","Inclusion Criteria:\n\n* Patients ≥ 6 years of age\n\n  * Newly diagnosed patients with plaque psoriasis with affected BSA \\>10%\n  * Indicated for a new systemic therapy (e.g., oral agent, biologics).\n  * Willing and able to provide informed consent for all procedures .\n  * At least one eligible, representative target plaque for serial dermoscopic imaging .\n  * Stop previous systemic therapy at least 2-3 months\n\nExclusion Criteria:\n\n* • Non cooperative patients .\n\n  * Pregnant or breastfeeding women","6 Years",{"count":89,"type":20},45,"OBSERVATIONAL","The goal of this observational study is to learn about the comprehensive changes in severe plaque psoriasis (Psoriasis Vulgaris) in adult participants undergoing standard treatment. The main questions it aims to answer are: How clinical signs of psoriasis, such as redness, scaling, and thickness, change after treatment? How specific skin features, visualized under dermoscopy, change after treatment? How participants' perceptions of psoriasis-related disability and overall quality of life improve after treatment? Participants will undergo standard medical treatment for severe psoriasis. Participants will be evaluated at the beginning of the study and again after treatment using clinical skin examinations, dermoscopic imaging, and validated questionnaires (Psoriasis Disability Index and quality of life parameters).",[26],"2026-03-24",{"date":95,"type":31},"2026-03-27",{"date":97,"type":20},"2026-05-01",{"date":99,"type":20},"2027-11-01",{"name":101,"class":38},"Assiut University",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100546681","phase-4-proactive-tdm-versus-standard-use-of-biologics-in-psoriasis-100546681","NCT06398106","Proactive TDM Versus Standard Use of Biologics in Psoriasis","Proactive Therapeutic Drug Monitoring Versus Routine Care With the Novel Biologics in Psoriasis : a Pragmatic, Multicentric, Randomised, Controlled Study","HELIOS","Inclusion Criteria:\n\n1. Adults; aged 18 years or older\n2. Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist\n3. Patients must be currently treated with secukinumab, ixekizumab or guselkumab ≥ 6 months according to the standard dosing scheme.\n4. The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures\n\nExclusion Criteria:\n\n1. Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication)\n2. Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc)\n3. Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PsA at inclusion\u002Fbaseline\n4. Presumed inability to follow the study protocol\n5. Active pregnancy wish",{"count":111,"type":20},210,[23],"Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring). Depending on the drug concentration, the interval between injections will be lengthened or shortened with the aim to reach the required drug concentration to reach the best clinical result. The trial will be conducted in 14 Belgian hospitals where patients will be divided into 2 study groups: a group that will be advised on the dosing scheme of their biologic based on the measured drug concentration and a group that continues dosing as in daily clinical practice. We will monitor if the clinical response and quality of life remains stable. With this study, we will track drug concentrations as we believe that they can guide dosing of biologics and we hope to achieve better safety, lower healthcare expenses and higher patients' treatment satisfaction while striving for the best clinical response.",[26],[116,117],"Therapeutic drug monitoring","Biologics","2026-03-02",{"date":120,"type":31},"2026-03-04",{"date":122,"type":31},"2024-12-20",{"date":124,"type":20},"2028-03-01",{"name":126,"class":38},"University Hospital, Ghent",15,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":139,"briefSummary":141,"conditions":142,"keywords":145,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":39},"100625706","phase-3-efficacy-and-safety-of-a-botanical-total-coumarin-tc-cream-in-treating-patients-with-psoriasis-vulgaris-plantcoat-iii-100625706","NCT07426120","Efficacy and Safety of a Botanical Total Coumarin (TC) Cream in Treating Patients With Psoriasis Vulgaris (PLANTCOAT-III)","A Double-blind, Randomized, Placebo-controlled, Parallel-controlled, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of a Botanical Total Coumarin Cream (TC Cream) in Treating Patients With Psoriasis Vulgaris","PLANTCOAT-III","Inclusion Criteria:\n\n* Age of 18-70 years old. Both men and women, and members of all races and ethnic groups\n* Consistent with the diagnostic criteria of stable phase psoriasis vulgaris, and have at least two target lesions suitable for evaluation\n* Women of childbearing age must be using birth control strategies defined by one of the following: 1) a barrier method (condom) and\u002For 2) oral contraceptives, during the 8-week study period.\n* ISGA score ≥ 2 (at least mild severity)\n* BSA (stable stage group): 1%≤ to ≤20%\n* Signed a written informed consent document\n* No additional exposure to the sun\n\nExclusion Criteria:\n\n* Subjects in pregnancy, preparing for pregnancy, or breastfeeding\n* History of hyperergic or photosensitivity\n* History of complicated cardiovascular diseases, cerebrovascular diseases, severe primary diseases of the hepatic, kidney, and hematopoietic system, or patients with psychiatric disorders\n* History of photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosa\n* Within 4 weeks prior to randomization, patients have taken treatment with the following approved or investigational psoriasis therapies on the target lesions:\n\n  * Topical treatments\n  * PUVA, UVB, or Grenz ray therapy.\n  * Any systemic treatments other than biologicals with a possible effect on psoriasis (e.g., corticosteroids, vitamin D analogues, hydroxycarbamide, azathioprine, methotrexate, cyclosporine, other immunosuppressants).\n  * Any types of other investigational therapies for psoriasis\n* Within 3 months prior to randomizations, patients have taken systemic treatments with retinoids or biological therapies (marketed or otherwise) with a possible effect on psoriasis (e.g., alefacept, efalizumab, etanercept, infliximab).\n* Planned initiation of, or changes to, concomitant medications that could affect psoriasis (e.g., beta blockers, anti-malaria drugs, lithium) during the double-blind phase of the study.\n* History of allergic reactions attributed to compounds of similar chemical or biologic compositions to Coumarins.","70 Years",{"count":138,"type":20},300,[140],"PHASE3","The goal of this clinical trial is to learn if a botanical Total Coumarin topical cream (TC Cream) works to treat psoriasis in adults. It will also learn about the safety of the topical TC Cream. The main questions it aims to answer are:\n\n* Does TC Cream improve the psoriasis disease symptoms?\n* What medical problems do participants have when applying TC Cream?\n* Does TC Cream improve the quality of life of psoriasis patients? Researchers will compare TC Cream to a placebo cream (a look-alike cream that contains no active drug) to see if TC Cream works to treat psoriasis.\n\nParticipants will:\n\n* Topically apply the TC Cream or a placebo cream twice daily every day to affected skin for 8 weeks\n* Visit the clinic once every 2 weeks for checkups and tests\n* Keep a diary of their symptoms and their diseased skin conditions during the application of the topical cream",[26,143,144],"Topical Administration","Phase III",[146,147,148,149,150],"Psoriasis","Topical cream","Botanical drug","FDA IND","NMPA approval","2026-02-15",{"date":153,"type":31},"2026-02-23",{"date":155,"type":31},"2026-02-01",{"date":157,"type":20},"2028-06-30",{"name":159,"class":160},"Psoriasis Research Institute of Guangzhou","INDUSTRY",{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":167,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":21,"phases":171,"briefSummary":172,"conditions":173,"keywords":174,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":184,"leadSponsor":186,"locationsCount":39},"100620029","phase-4-topical-diacerein-in-psoriasis-vulgaris-100620029","NCT07352306","Topical Diacerein in Psoriasis Vulgaris","The Efficacy of Topical Diacerein Cream in Patients With Psoriasis Vulgaris","DIA","Inclusion Criteria:\n\n* Age ≥18 years old of both genders.\n* Patients with mild chronic plaque psoriasis body surface area (BSA \\\u003C 10%) along with Psoriasis Area and Severity Index (PASI) score of \\\u003C 10, and\u002For Dermatology Life Quality Index (DLQI) score of \\\u003C10.\n\nExclusion Criteria:\n\n* Documented hypersensitivity or idiosyncratic reaction to the investigational product or any excipients contained within the cream formulation.\n* Intake of anti-psoriatic systemic therapy within the last 3 months, or topical treatments within the last 2 weeks.\n* Patients with pustular psoriasis.\n* Pregnant and breast-feeding individuals.\n* Patients with psoriatic arthritis.",{"count":170,"type":20},60,[23],"The goal of this clinical trial is to evaluate the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the placebo group.\n\nParticipants will:\n\nBe assigned to receive topical diacerein 1% or placebo twice daily for a treatment period of 2 months.\n\nAttend follow-up visits at Weeks 2, 4, 6, and 8. Undergo an additional evaluation one month after treatment cessation.",[26],[175,176,177,178,179],"Diacerein","Psoriasis vulgaris","Topical","Interleukin-1β inhibitor","Randomized controlled trial","2026-01-11",{"date":182,"type":31},"2026-01-20",{"date":155,"type":20},{"date":185,"type":20},"2027-05-01",{"name":79,"class":38},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":15,"minAge":16,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":39},"100617611","correlation-between-vaspin-gene-polymorphism-and-serum-vaspin-levels-in-psoriasis-vulgaris-100617611","NCT07320872","Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris","Correlation Between Vaspin Gene Polymorphism and Serum Vaspin Levels in Psoriasis Vulgaris and Its Relation to Pathogenesis and Risk of the Disease","Inclusion Criteria:\n\n* Newly diagnosed cases or stopped treatment of at least 6 months of psoriasis patients.\n* Pateints with any age and gender.\n\nExclusion Criteria:\n\n* Pregnancy and lactation.\n* Patients with chronic diseases: cardiac diseases, hepatic disorders, chronic renal failure or malignancies.\n* Patients with associated inflammatory disease such as infections and autoimmune diseases.",true,"50 Years",{"count":170,"type":20},"Psoriasis is a common immune-mediated inflammatory skin disease affecting at least 100 million individuals worldwide. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3% of the Egyptian people.\n\nIt is associated with poor quality of life, reduced life expectancy and multimorbidity including psoriatic arthritis, obesity and cardiovascular disease.\n\nVaspin (VASP, SERPIN 12) is a recently discovered adipokine that has been isolated from the visceral adipose tissue of a rat model of type 2 diabetes. It is coded by the gene SERPNA12 located on the long arm of chromosome 14q32.13 and consists of six exons and five introns.",[26],"2025-12-22",{"date":201,"type":31},"2026-01-06",{"date":203,"type":31},"2025-08-10",{"date":205,"type":20},"2026-08-20",{"name":207,"class":38},"Aswan University",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":90,"phases":4,"briefSummary":218,"conditions":219,"keywords":242,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":39},"100435439","prevalence-and-risk-factors-associated-with-cardiac-comorbidity-in-psoriasis-100435439","NCT04950218","Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA: Prevalence and Risk Factors asSOciated With CArdiac comorbiDIty in psoriAsis","PSOCADIA","Inclusion Criteria:\n\n* Patients 18 years or older with a diagnosis of psoriasis will be invited to participate\n\nExclusion Criteria:\n\n* Patients not able to cooperate to the study\n* Patients unable understand and sign informed consent",{"count":217,"type":20},1000,"In a prospective cohort study (n = 1.000), the investigators aim to investigate the correlation between cardiac biomarkers and advanced echocardiography and determine whether these are prognostic markers of heart disease in patients suffering from psoriasis.",[146,220,221,222,26,223,224,225,226,227,228,229,230,231,232,233,234,235,236,237,238,239,240,241],"Cardiovascular Diseases","Cardiovascular Risk Factor","Cardiovascular Pathology","Psoriatic Nail","Psoriasis Face","Psoriasis Guttate","Psoriasis Gyrata","Psoriasis Diffusa","Psoriasis Palmaris","Psoriasis Annularis","Psoriasis Circinata","Psoriasis Plantaris","Psoriasis Universalis","Psoriasis Geographica","Left Ventricular Dysfunction","Myocardial Infarction","Myocardial Ischemia","Heart Failure","Stroke","Heart Diseases","Heart Failure, Systolic","Heart Failure, Diastolic",[146,243,244,245,246,247],"Echocardiography","Advanced echocardiography","Biomarkers","Mortality","Cardiovascular mortality","2025-09-09",{"date":250,"type":31},"2025-09-15",{"date":252,"type":31},"2021-09-01",{"date":254,"type":20},"2034-10-01",{"name":256,"class":38},"Herlev and Gentofte Hospital",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":21,"phases":267,"briefSummary":268,"conditions":269,"keywords":270,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":280},"100368693","therapeutic-drug-monitoring-of-brodalumab-in-psoriasis-patients-bioloptim-bro-100368693","NCT04080635","Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)","Evaluation of the Predictive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Brodalumab and the Development of Concentration-response Curve of Brodalumab of Psoriasis Patients.","BIOLOPTIM-BRO","Inclusion Criteria:\n\n1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis\n2. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study\n\nExclusion Criteria:\n\n1. Participants who have currently a predominant nonplaque form of psoriasis\n2. Participants who are pregnant, nursing or planning a pregnancy\n3. Participants who are unable or unwilling to undergo multiple venapunctures\n4. Participants who are treated according to a different dosing schedule than standard dosing of brodalumab",{"count":266,"type":20},100,[67],"Biologics, such as brodalumab, are currently the most effective treatment option for patients with moderate-to-severe psoriasis. But they are costly for health care systems and prescribed according to a 'one dose fits all' dosing regimen, leading to potential over- and undertreatment. Within this study we aim to investigate the predictive value of early serum trough levels of brodalumab and determine the therapeutic window of brodalumab in psoriasis patients.",[26],[146,116,271],"Brodalumab","2024-09-05",{"date":274,"type":31},"2024-09-19",{"date":276,"type":31},"2018-12-14",{"date":278,"type":20},"2024-12-31",{"name":126,"class":38},7,{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":288,"enrollmentInfo":289,"targetDuration":4,"studyType":21,"phases":291,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":4},"100555152","topical-thymoquinone-in-psoriasis-vulgaris-100555152","NCT06508372","Topical Thymoquinone in Psoriasis Vulgaris","Efficacy and Safety of Thymoquinone Ointment as a Potential New Therapeutic Modality of Psoriasis Vulgaris.","Inclusion Criteria:\n\n* Patients with clinical diagnosis of mild psoriasis vulgaris\n* Age: between 18 and 60 years' old\n* Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment\n\nExclusion Criteria:\n\n* Psoriasis vulgaris involving \\> 10% of the body surface area, pustular or erythrodermic psoriasis.\n* Pregnant or lactating females.\n* Patients with any current dermatological disease.\n* Patients with any current systemic disease.","60 Years",{"count":290,"type":20},30,[67],"A previous trial found that N. sativa oil was more effective as an antipsoriatic agent, particularly when taken as both a cream and a pill. This confirmed that N. sativa possesses antipsoriatic properties and can alleviate psoriasis symptoms",[26],[295],"topical thymoquinone","2024-07-18",{"date":298,"type":31},"2024-07-19",{"date":300,"type":20},"2024-08-01",{"date":302,"type":20},"2025-01",{"name":101,"class":38},{"id":305,"slug":306,"hasResults":11,"nctId":307,"briefTitle":308,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":288,"enrollmentInfo":311,"targetDuration":4,"studyType":21,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":315,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":320,"leadSponsor":322,"locationsCount":4},"100531720","phase-4-botox-versus-tacrolimus-in-psoriasis-vulgaris-100531720","NCT06203470","Botox Versus Tacrolimus in Psoriasis Vulgaris","Efficacy and Safety of Mesobotox as a Potential New Therapeutic Modality of Psoriasis Vulgaris in Comparison\u002FCombination With Topical Calcineurin Inhibitor","Inclusion Criteria:\n\n* Patients with clinical diagnosis of mild to moderate psoriasis vulgaris\n* Patients who stopped any systemic therapy or phototherapy for at least 3 months and topical therapy for at least 4 weeks prior to enrollment.\n\nExclusion Criteria:\n\n* • Psoriasis vulgaris involving \\> 10% of the body surface area, pustular or erythrodermic psoriasis.\n\n  * Patients with neuromuscular disease or history of epilepsy.\n  * Pregnant or lactating females.\n  * Patients with any current dermatological disease.\n  * Patients with any current systemic disease.",{"count":170,"type":20},[23],"Psoriasis is a systemic chronic relapsing immune-mediated disease which often requires a long-term therapy. Psoriasis occurs in around 2-3% of the total global population. In Egypt, the prevalence of psoriasis ranges between 0.19% and 3%.\n\nBesides, it could have profound implications on the patients' psychological state and quality of life.\n\nIt is presented by erythematous, scaly plaques over the preferred sites. The pathogenesis of this highly complex disease is still far from being fully understood. Keratinocytes' hyperproliferation and immune system dysfunctions are well recognized contributors, with numerous treatments targeting these unique immunologic dysfunctions.",[26],"2024-06-11",{"date":317,"type":31},"2024-06-12",{"date":319,"type":20},"2024-06",{"date":321,"type":20},"2026-10",{"name":101,"class":38}]